Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jules Quartly
The market debuts of BeiGene and Ascletis on the new Hong Kong Stock Exchange’s Biotech section could further encourage other Chinese biotech companies as they seek to draw in a wider pool of investors and focus on the promising domestic sector.
Multinationals and M&A deals could be adversely affected by new measures in China that could delay or even block the export of intellectual property out of the country.
The introduction of new listing rules in Hong Kong makes it easier for biotech companies to go public and provides incentives for both China-based and international companies to float there rather than in New York or elsewhere, although some concerns linger.
The biggest shakeup of the Hong Kong Stock Exchange for three decades could see biotech businesses and innovators turn from West to East when seeking listings, as shown by plans being made by two prominent Chinese bioventures.
While there have been a number of positive changes in the operating and regulatory environment in China, pharmaceutical companies will still need a focused strategy to succeed in the country’s increasingly competitive but potentially lucrative oncology market, according to one expert.
Solid fundamentals in the Asia-Pacific healthcare market are continuing to attract significant investment and M&A activity with no signs of a slowdown, despite fears over China’s economic growth and negative factors in the wider global economy. Medtech, digital health and health services are all set to benefit, experts say.